ArriVent Announces Phase 1 Data for ARR-217 ADC

NEWTOWN SQUARE, PA, USA - ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced initial Phase 1 results for ARR-217, a cadherin-17 (CDH17)-targeting antibody-drug conjugate, in patients with gastrointestinal cancers at the ESMO Congress 2026.

The ongoing multicenter Phase 1 study evaluated ARR-217 in 123 heavily pretreated patients with gastrointestinal malignancies. Data showed strong anti-tumor activity, particularly in colorectal cancer patients, and the therapy demonstrated a manageable safety profile.

Key Highlights

• Objective response rate of 44.8 percent at the 6 mg/kg dose in pre-treated colorectal cancer patients.
• Disease control rate of 93.1 percent at the 6 mg/kg dose.
• Generally well-tolerated safety profile with common adverse events being Grade 1 or 2.

ArriVent has advanced ARR-217 into a Phase 1b dose optimization study at doses of 5 and 6 mg/kg, with further data expected in 2027.